A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression
2011

TAS106 Enhances Radiation Sensitivity in Cancer Cells

publication Evidence: moderate

Author Information

Author(s): Meike Shunsuke, Yamamori Tohru, Yasui Hironobu, Eitaki Masato, Matsuda Akira, Morimatsu Masami, Fukushima Masakazu, Yamasaki Yasundo, Inanami Osamu

Primary Institution: Hokkaido University

Hypothesis

Does TAS106 modify the repair capacity of DNA double-strand breaks in tumor cells?

Conclusion

TAS106 induces down-regulation of BRCA2, leading to impaired DNA repair and enhanced radiosensitivity in cancer cells.

Supporting Evidence

  • TAS106 enhanced radiosensitivity in A549, HEp-2, and V79 cell lines.
  • Pretreatment with TAS106 reduced the D10 of surviving fraction in V79 cells.
  • TAS106 suppressed the expression of BRCA2 and Rad51, key proteins in DNA repair.

Takeaway

TAS106 is a drug that makes cancer cells more sensitive to radiation by stopping them from fixing their damaged DNA.

Methodology

The study used clonogenic survival assays and immunocytochemistry to assess the effects of TAS106 on DNA repair in various cell lines.

Limitations

The study primarily focused on specific cell lines and may not generalize to all tumor types.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1476-4598-10-92

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication